We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ORTHOHELIX GETS FDA WARNING LETTER FOR MDR DEFICIENCIES

ORTHOHELIX GETS FDA WARNING LETTER FOR MDR DEFICIENCIES

April 25, 2006

Ohio-based OrthoHelix Surgical Designs has received a warning letter from the FDA for failing to report a Class II recall initiated last fall.

The recall involved the company's MaxLock driver system, designed for foot and ankle internal fixation. According to the OrthoHelix website, the system contains 10 plate sizes, two screws and a variety of instruments, including a driver.

When reports emerged that the pilot tip on the MaxLock was breaking, the firm ordered a field correction and removal. OrthoHelix initiated the action last November, but the FDA first became aware of the recall after a Jan. 1031 inspection, the letter states.

"Even if you believed you were not required to report the correction or removal to FDA, you did not have a written justification for not reporting this action to FDA," the agency wrote in its recent letter to the firm. The agency noted that it considers the product to be misbranded.

Design input requirements for the MaxLock were "incomplete and ambiguous," the letter said, citing as examples that "the intended population [is] not described, [the] environment in which the product is intended to be used is not characterized, interfaces with instrumentation [are] not detailed, human factors requirements [are] not addressed, mechanical performance specifications [are] not listed for the screws and plates, and no descriptive information [is provided] regarding such specifications as: radius edges, low profile, and nonlocking screw/plate interface."

Furthermore, "the design verification results, including identification of the design, methods, the date, and the individual performing the verification, were not documented and filed in the design history file," the letter said. As an example, the agency cited a lack of document review after a contract laboratory provided mechanical testing on the MaxLock system.

The letter also pointed out that "procedures for validating the device design were not complete," noting that the device's validation plan did not define the sizes and shapes of system components being tested, or whether the implants were to be used for hand or foot surgery.

Finally, the "design verification did not confirm that the design output meets the design input requirements," the agency said.

OrthoHelix did not respond to a request for comment by FDAnews press time. To access the warning letter, visit http://www.fda.gov/foi/warning_letters/g5797d.htm (http://www.fda.gov/foi/warning_letters/g5797d.htm). ()a href="http://www.fdanews.com/ddl/33_17/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing